As part of a WIPO program to unify the look and feel of its products, PATENTSCOPE is changing.
Try the new PATENTSCOPE look and feel. You can switch back from the Help > More menu
A method of treating female infertility using a novel cetrorelix acetate lyophilizate is disclosed.
A novel lyophilizate and method of preparation as well as the use of the lyophilizate to treat female infertility and for gonad protection. Cetrorelix is dissolved in acetic acid 30% v/v, the solution is transferred to water and freeze dried.
Disclosed herein is the use of TRAP per se as an active ingredient for the manufacture of a medicament for the treatment of Staphylococcus aureus infection. An exogenous TRAP (native TRAP or recombinant TRAP) per se can effectively inhibit the production of Staphylococcus aureus exotoxins, thereby reducing the pathogenicity of Staphylococcus aureus. In addition, a medicament including TRAP also stimulates the production of corresponding antibodies in human body at the time when it is used to treat Staphylococcus aureus infections, and these antibodies can further inhibit the production of Staphylococcus aureus exotoxins. Such double actions increase the effects of medicament and provide a novel medicament action mode. Moreover, since TRAP functions merely to the toxicity of bacteria but does not affect the growth of bacteria, it cannot make bacteria readily develop drug resistance, and also effective to drug resistant Staphylococcus aureus. Moreover, no homologous sequence of the TRAP proteins is found in human genome, so that the medicaments of TRAP cannot cause human immunologic diseases.
A multi-step process for purifying an immune serum globulin fraction from a crude plasma protein fraction involves precipitating non-serum globulin proteins from an aqueous suspension of the crude plasma protein fraction using a protein precipitant, adding a virus-inactivating agent to the clarified immune serum globulin-containing liquid, absorbing the immune serum globulins onto a cation exchange resin and washing non-serum globulin contaminants from the resin, subjecting the eluate to ultrafiltration to concentrate the immune serum globulins and separate them from low molecular weight species, contacting the concentrate with an anion exchange resin to absorb non-serum globulin contaminants, passing the imune-serum globulins through the anion exchange resin under conditions that leave non-serum globulin contaminants bound to the resin, and subjecting the filtrate to a molecular washing step to produce a purified immune serum globulin fraction. This process results in products substantially free of active viruses and contaminating lipids, activated complements and low molecular weight peptides. In addition, the process is advantageous in terms of efficiency and adaptability to large-scale production.
A composition for treating or preventing a Th2-dysregulated inflammatory condition wherein the composition comprises a therapeutically effective amount of one or more IDR peptides. Use of IDR peptides or a composition comprising IDR peptides for treating or preventing a Th2-dysregulated inflammatory condition. The Th2-dysregulated inflammatory condition includes allergy or atopy, for example allergic asthma.
